Neuromyelitis optica (NMO) is an inflammatory CNS disorder that preferentially affects the optic nerve and spinal cord. The discovery of aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies as a specific biomarker of NMO led in 2006 to the development of revised NMO diagnostic criteria that required both optic neuritis and myelitis and AQP4-IgG seropositivity as supportive criteria.^[@R1]^ In 2007, the term NMO spectrum disorders (NMOSD) was introduced to include AQP4-IgG-seropositive patients with limited or inaugural forms (e.g., recurrent optic neuritis or longitudinally extensive transverse myelitis \[LETM\]), or with manifestations outside of the optic nerve and spinal cord (e.g., hiccups or nausea and vomiting).^[@R2]^

In 2015, an International Panel proposed new diagnostic criteria that unify patients with typical NMO and the more recently defined NMOSD under the term NMOSD.^[@R3]^ These criteria are based on the presence or absence of AQP4-IgG and on the assumption that patients with limited forms (NMO/LF) will develop typical NMO over time.^[@R2],[@R3]^ However, in some patients the interval between the disease-defining events of optic neuritis and myelitis and conversion to NMO may be years or decades.^[@R2],[@R4],[@R5]^ Why some patients remain with limited forms for prolonged periods of time and if having a limited form impacts disability outcomes are unknown. Both the 2006 and the 2015 criteria allow the diagnosis of NMO or NMOSD, respectively, in patients without AQP4-IgG.^[@R6],[@R7]^ Recent studies have shown that some of these patients have antibodies to myelin oligodendrocyte glycoprotein (MOG).^[@R7][@R8][@R9]^ Moreover, studies suggest that the clinical outcome of patients with NMO and MOG-IgG is different from that of patients with NMO with AQP4-IgG or who are double seronegative.^[@R7],[@R9]^

These questions are important because in the newly proposed criteria different clinical phenotypes such as NMO or NMO/LF are no longer considered. To address this, we analyzed the demographic and clinical features of a Spanish cohort of patients with NMOSD with AQP4-IgG who had either the NMO phenotype (2006 criteria) or NMO/LF to identify predictors of conversion to NMO and impact on disability outcomes. We also reviewed the clinical outcomes of patients with the NMO phenotype according to the presence or absence of AQP4-IgG or MOG-IgG.

METHODS {#s1}
=======

Case selection and data collection. {#s1-1}
-----------------------------------

Clinical information and samples for this observational, retrospective, multicenter study were collected from 59 centers through the multiple sclerosis (MS) study group of the Spanish Society of Neurology and the Spanish MS Network (Red Española de Esclerosis Múltiple) from January 2013 to January 2015. Overall, 181 patients who at last follow-up fulfilled the 2006 NMO criteria (n = 127) or had NMO/LF associated with AQP4-IgG (n = 54) were included.^[@R1],[@R2]^ Epidemiologic data, including demographic, clinical, CSF (cell count, protein levels, and oligoclonal bands), MRI findings (brain MRI classified as normal and abnormal with or without the Paty or Barkhof criteria,^[@R10]^ and number and extension of spinal cord lesions), treatment, and outcome, were obtained from medical records and information collected from referring neurologists through a structured questionnaire designed for NMO. All serum samples were tested for AQP4-IgG by immunohistochemistry and an in-house cell-based assay (CBA) with live HEK293 cells transfected with the aquaporin-4-M23 isoform as reported.^[@R9],[@R11]^ All but 5 samples from AQP4-IgG-seropositive and 4 seronegative cases were tested for MOG-IgG using an in-house CBA with HEK293 cells transfected with the full-length MOG C-terminally fused to EGFP.^[@R9]^ The outcome reached at last follow-up was evaluated by the Expanded Disability Status Scale (EDSS) score.^[@R12]^ Severe visual disability was defined as sustained visual acuity ≤20/100 with best correction possible during at least 6 months after an optic neuritis attack.

Standard protocol approvals, registrations, and patient consents. {#s1-2}
-----------------------------------------------------------------

The study was approved by the Ethics Committee of the Hospital Clinic, and written consent was obtained for all participants. Samples were deposited in a registered biobank of the Institut d´Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Statistical methods. {#s1-3}
--------------------

Characteristics were compared between patient groups using χ^2^ (or Fisher exact) tests for categorical data and Student *t* test (or Wilcoxon rank sum) for continuous data. The Kaplan-Meier method was used to estimate the time to first and second recurrence, conversion to NMO phenotype, onset of chronic therapy, and to reach EDSS scores of 6 and 8. Survival curves were compared using log-rank tests and predictive factors for disability were assessed with Cox proportional hazards regression models. Disease characteristics along the disease course were compared using regression models with generalized estimating equations, logistic regression for binary data, and linear regression for continuous data, and adjusted by the follow-up time for each patient. Age, sex, ethnicity, type of syndrome at onset, and severity after the first event were included as predictive factors for conversion, and annualized relapse rate was added as predictive factor for disability. Chronic therapy was included as a time-dependent covariable in both analyses. Two-sided *p* values \<0.05 were considered statistically significant. Analyses were performed using SPSS version 19.0.

RESULTS {#s2}
=======

Demographic, clinical, and serologic characteristics of the cohort. {#s2-1}
-------------------------------------------------------------------

Clinical and demographic data of the 181 patients are summarized in [table 1](#T1){ref-type="table"}. The median age at disease onset was 39 years (range 10--77 years) and the disease duration 6.4 years (0.2--50 years). Patients were mainly white (86%), with a female:male ratio of 6.5:1. The frequency of optic neuritis or transverse myelitis presentation at onset was similar (38% and 40%, respectively); simultaneous or sequential (\<1 month from onset) optic and spinal attacks were infrequent (14%). The clinical phenotype and disease course at the last follow-up is detailed in figure e-1 at [Neurology.org/nn](10.1212/NXI.0000000000000225). All but 20 patients (11%) had a relapsing course, and 150 (83%) were on chronic therapy. In total, 148 patients (82%) had AQP4-IgG, 9 (5%) MOG-IgG, 2 (1%) both, and 22 (13%) were double seronegative. The 2 patients with both antibodies were excluded from the analyses of clinical-immunologic correlates.

###### 

Demographic and disease characteristics of the cohort

![](NEURIMMINFL2016009019TT1)

Demographic and clinical differences between AQP4-IgG-positive NMO patients and those who remained with NMO/LF. {#s2-2}
---------------------------------------------------------------------------------------------------------------

Examining the entire cohort of 148 AQP4-IgG patients showed those with NMO/LF presented more frequently with LETM at first (*p* \< 0.001) and second attack (*p* = 0.003) than those with NMO ([table 2](#T2){ref-type="table"}). The age at disease onset of the patients who presented with LETM and remained as NMO/LF was older than those who developed the NMO phenotype (median 47 vs 34 years, *p* \< 0.001).

###### 

Demographic and clinical features and outcome of AQP4-IgG-positive patients with NMO or NMO/LF

![](NEURIMMINFL2016009019TT2)

We investigated which variables predicted conversion to NMO in this cohort. We found that nonwhite ethnicity doubled the risk as compared with white race (hazard ratio \[HR\] 2.2, 95% confidence interval \[CI\], 1.2--3.9, *p* = 0.008); optic neuritis increased the risk 2-fold as compared with LETM presentation (HR 2.2, 95% CI 1.2--3.9, *p* = 0.008) and almost 4-fold as compared with brainstem attack (HR 3.9, 95% CI 1.2--13.0, *p* = 0.024). Age at disease onset only influenced the risk for developing NMO in those who presented with LETM, being lower for older patients (30--40 years, HR 0.19, 95% CI 0.07--0.55; ≥50 years HR 0.054, 95% CI 0.01--0.27; compared with \<30 years, *p* \< 0.0001). The 5-year conversion risk to NMO was 63.2% (95% CI 48%--78%) for optic neuritis, 41.4% (95% CI 26%--57%) for LETM, and 23% (95% CI 1%--46%) for brainstem syndrome ([figure 1A](#F1){ref-type="fig"}).

![Kaplan-Meier estimation of time to neuromyelitis optica (NMO) conversion and development of motor disability\
(A) Months from onset to develop NMO according to the onset attack type: patients with optic neuritis, and those with longitudinally extensive transverse myelitis (LETM) aged \<30 years, converted earlier than patients with LETM aged \>30 years or with brainstem syndrome (*p* \< 0.001). (B) Months from onset to use a cane (Expanded Disability Status Scale \[EDSS\] score 6.0) by age at disease onset: older patients were significantly more likely than younger patients to develop motor disability over time (*p* \< 0.001). (C) Years from onset to use a cane by antibody status in NMO patients: at 5 years after onset, 26% of aquaporin-4 immunoglobulin G (AQP4-IgG)--positive patients, 19% of double-seronegative patients, and none of the myelin oligodendrocyte glycoprotein (MOG)--IgG-positive patients were expected to need a cane to walk (EDSS score 6.0) (*p* = 0.089). EDSS score 6.0 = intermittent or unilateral assistance required to walk 100 meters with or without resting. ON = optic neuritis.](NEURIMMINFL2016009019FF1){#F1}

Regarding disease severity, the mean annualized relapse rate (ARR) for the patients who remained with NMO/LF was significantly lower ([table 2](#T2){ref-type="table"}); the mean number of relapses remained lower after adjusting for time of follow-up (3 vs 4.8, *p* = 0.018). NMO/LF patients who remained monophasic had significantly shorter disease duration than those who relapsed (median 2 vs 5.5 years, *p* \< 0.001). Patients with NMO/LF were treated earlier than those with NMO (median time from disease onset to therapy initiation 6.3 months \[interquartile range (IQR) 3.7--18.6 months\] vs 17.7 months \[IQR 5.6--60 months\], *p* = 0.014), and had a better response; the mean (SD) ARR after treatment decreased to 0.3 (0.6) in NMO/LF and 0.7 (0.8) in NMO patients, *p* = 0.035. Seventy of the 84 patients (83%) who received chronic therapy were treated after fulfillment of NMO criteria (e-Results).

The EDSS score at last follow-up was significantly lower in those who remained NMO/LF than in patients with NMO ([table 2](#T2){ref-type="table"}), but the difference was due to the lower EDSS score of the patients who remained as optic neuritis (median 2.0, range 1.0--4.0) or brainstem syndrome (median 1.0, range 0--2.0). When we compared the motor disability of patients with NMO with that of patients who remained with LETM, no significant differences were found in the proportion of patients who reached severe disability (EDSS score of 6.0). There was also no difference in the percentage of patients with severe visual disability (visual acuity ≤20/100) when comparing patients with NMO with those who remained with optic neuritis ([table 2](#T2){ref-type="table"}). The same results were found after adjusting for time of follow-up (motor disability: odds ratio \[OR\] 0.69, 95% CI 0.3--1.6, *p* = 0.385; visual disability: OR 1.027, 95% CI 0.29--3.65, *p* = 0.970).

Predictors for disability in patients with AQP4-IgG. {#s2-3}
----------------------------------------------------

In the analyses for the development of disability, we found that nonwhite ethnicity (HR 4.3, 95% CI 1.4--13.6, *p* \< 0.012), older age at disease onset (HR 1.7 for every 10-year increase in age at onset; 95% CI 1.3--2.2, *p* \< 0.0001) ([figure 1B](#F1){ref-type="fig"}), and higher residual disability after first attack increased the risk of requiring a cane to walk (EDSS 6.0) (HR 1.3, 95% CI 1.1--1.6, *p* = 0.017). In the analysis for visual outcome, older age at disease onset (OR 1.9 for every 10-year increase in age at onset; 95% CI 1.2--2.9, *p* = 0.005), higher disability after the first attack (OR 1.7, 95% CI 1.1--2.6, *p* = 0.015), and time of follow-up (by year, OR 1.2, 95% CI 1.1--1.3, *p* = 0.028) were associated with worse visual outcome. No significant effect was observed in association with ethnicity, initial syndrome, ARR, or chronic therapy.

Demographic and clinical differences among patients with NMO phenotype according to antibody status. {#s2-4}
----------------------------------------------------------------------------------------------------

Patients with NMO and AQP4-IgG had a significantly higher female:male ratio (14.7:1) than patients who were double seronegative (1.4:1) or with MOG-IgG (0.8:1), *p* \< 0.001 ([table 3](#T3){ref-type="table"}; table e-1). At last follow-up, patients with MOG-IgG had a lower median EDSS score (1.0, range 0--3.0) than those with AQP4-IgG (4.5, range 1.0--9.0) and those who were double seronegative (5.0, range 0--9.0), *p* \< 0.001 ([table 3](#T3){ref-type="table"}). Due to the small sample size and the fact that none of the patients with MOG-IgG reached the EDSS score of 6.0, only a trend to lower risk of motor disability was observed in comparison with AQP4-IgG and double seronegative patients (log-rank test, *p* = 0.089) ([figure 1C](#F1){ref-type="fig"}). There were no differences among the 3 groups in severity of disease at onset, time to first relapse, ARR, and frequency of relapses within 1 or 2 years of onset ([table 3](#T3){ref-type="table"}). The median delay to start therapy was not significantly different among the groups (around 0.5--1.5 years), and the comparative analyses of the effect of therapy on relapse rate did not reveal significant differences; after therapy, the mean (SD) ARR for AQP4-IgG patients decreased from 3.6 (5.5) to 0.7 (0.8), for double seronegative from 3.2 (3.7) to 0.6 (1.1), and for MOG-IgG from 5.2 (3.9) to 0.1 (0.2) (*p* = 0.400) (e-Results).

###### 

Comparison of demographic and clinical characteristics of patients with NMO (fulfilling the 2006 NMO criteria) according to antibody status

![](NEURIMMINFL2016009019TT3)

DISCUSSION {#s3}
==========

This study of a large cohort of NMO patients identified by uniform criteria and sensitive assays for AQP4-IgG and MOG-IgG detection provides several important observations: (1) the median time of conversion to NMO in patients with AQP4-IgG who develop the NMO phenotype is 1 year; however, there is a subgroup of patients with AQP4-IgG who do not convert to NMO after a median follow-up of 5 years; (2) presentation with optic neuritis and nonwhite ethnicity are predictors of NMO conversion; (3) the final motor or visual disability outcome of patients with AQP4-IgG who do and do not convert to NMO is the same; (4) older age and nonwhite ethnicity are predictors of worse disability outcome irrespective of syndrome; (5) patients with NMO and AQP4-IgG and those who are double seronegative have similar clinical profiles in terms of relapses and disability; and (6) patients with NMO and MOG-IgG have better outcomes compared to patients with NMO and AQP4-IgG or who are double seronegative.

The 2015 proposed diagnostic criteria unifying the traditional NMO and modern NMOSD definitions for patients with AQP4-IgG was predicated on an absence of differences in clinical behavior, immunopathogenesis, and treatment of these patients.^[@R3]^ Our results support this aspect of the criteria as we found that all AQP4-IgG-seropositive patients have similar motor or visual disability outcomes.

We observed that presentation as optic neuritis increased the risk of developing NMO compared with presentation as LETM, but this was only significant for those patients with LETM aged ≥30 years. The higher risk of developing NMO in patients who present with optic neuritis was also observed in a previous study of patients with AQP4-IgG-seropositive NMOSD, although the influence of age was not noticed.^[@R5]^ Similarly, these authors also found a greater likelihood of developing NMO in Afro-Caribbean patients than Caucasians,^[@R5]^ supporting a contribution of genetic factors to the course of the disease.

Our results confirm previous observations that patients with AQP4-IgG who remain as NMO/LF present more frequently with LETM and are older than those who convert to NMO.^[@R5],[@R13],[@R14]^ The cause of the lower risk for patients with LETM to develop NMO is not clear. In our cohort of AQP4-IgG-positive patients, those with LETM were treated earlier than those with optic neuritis, and immunotherapy could have prevented the development of NMO. However, early treatment would not explain the differences observed between younger (\<30 years) and older (≥50 years) patients with LETM. Moreover, in patients with NMO/LF, the time to therapy initiation was not significantly different between patients who presented with optic neuritis or LETM.

There is widespread acceptance that attack prevention with immunosuppressant therapies is effective in reducing NMO relapses, and our study confirms a significant reduction in the relapse rate in both AQP4-IgG NMO and NMO/LF groups. The fact that patients with AQP4-IgG NMO/LF who remained monophasic had significantly shorter disease duration than those who relapsed supports the need of a follow-up of at least 5 years to qualify as a monophasic disease course, as suggested by the 2015 criteria.^[@R3]^ The contribution, however, of early therapeutic intervention to modulate the natural history of NMO/LF remains unclear and will only be ascertained with prospective studies in which clinical phenotype classification will be relevant. Until these studies are done, as disability outcome is similar for patients with AQP4-IgG who do and do not convert to NMO, as well as for patients who are double seronegative, early preventive therapy is warranted in these patients.

The 2015 criteria allow the diagnosis of NMOSD in patients without AQP4-IgG.^[@R6],[@R7]^ This is a matter of debate. Previous studies showed some clinical differences between AQP4-IgG-positive and -negative patients,^[@R15]^ including a lower female predominance in those without AQP4-IgG,^[@R4],[@R6]^ similar to the findings in the current study (1.4 vs 14.7). The phenotypic variability between AQP4-IgG-positive and -negative patients may be partially explained by the presence of MOG-IgG in a subgroup of the AQP4-IgG-seronegative patients. In the current study, we identified MOG-IgG in 29% of patients who would have been classified as seronegative. Compared to AQP4-IgG-seropositive or double-seronegative patients, those with MOG-IgG showed a male predominance, more often presented with simultaneous or sequential (\<1 month from onset) optic and spinal attacks, and more commonly had a monophasic disease course. Additionally, these patients had better outcomes even though the severity of disability during the initial attack and relapse rates were similar to the AQP4-IgG-seropositive or double-seronegative patients. These data and prior studies confirm the distinct prognosis for patients with MOG-IgG,^[@R7],[@R9],[@R16]^ and support the importance of testing for MOG-IgG. Moreover, our study confirms that double-positive cases are very rare. The 2 double-positive patients presented with simultaneous optic neuritis and LETM, and had a typical relapsing course. This is in contrast with a recently reported case that presented with an acute demyelinating encephalomyelitis and developed a fulminant clinical course.^[@R17]^

Even with the addition of MOG-IgG testing, 19% of patients in our study remained seronegative. This group of patients had similar clinical features and disability outcome to AQP4-IgG-seropositive patients, consistent with a recent report of the Mayo Clinic.^[@R6]^ For example, the percentage of AQP4-IgG-seropositive patients who relapsed within the first (51%) or second (62%) year after onset, and the estimated median time to require a cane (15 years), was similar.^[@R6]^ The challenge will be to determine if the seronegativity of this group is due to a lack of sensitivity of current antibody assays or the presence of uncharacterized immune responses. Additionally, it is likely that this is not a clinically homogenous group, highlighting the importance of collecting detailed phenotypic and epidemiologic data.

Our study has limitations related to its retrospective nature, and the ascertainment bias related to selection of patients who fulfilled the 2006 and 2007 definitions that were more restrictive than the recently proposed criteria. However, our findings in this large cohort of patients support the unified definition of NMOSD for seropositive AQP4-IgG patients, and provide novel serologic and clinical predictors of outcome.
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AQP4-IgG

:   aquaporin-4 immunoglobulin G

ARR

:   annualized relapse rate

CBA

:   cell-based assay

CI

:   confidence interval

EDSS

:   Expanded Disability Status Scale

HR

:   hazard ratio

IQR

:   interquartile range

LF

:   limited forms

MOG

:   myelin oligodendrocyte glycoprotein

MS

:   multiple sclerosis

NMO

:   neuromyelitis optica

NMOSD

:   neuromyelitis optica spectrum disorders

OR

:   odds ratio
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